Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sutent Fails to Show Efficacy for Breast Cancer in All 4 of the PIII Trials
June 28, 2010
- Korosho's Panel Begins Discussions for Early Diagnosis of COPD
June 28, 2010
- Hisamitsu, Kyowa Kirin Launch Fentos Tape for Relief of Cancer Pain
June 28, 2010
- Maintenance Therapy with Rituximab Halves Risk of Recurrent Lymphoma
June 28, 2010
- Takeda Launches 3 New Products Aiming at Combined Sales of ¥10 Bil. in 1st Year
June 28, 2010
- Speed Is Key to Success of sanofi-aventis Nichi-Iko: Dr Chocat
June 28, 2010
- Denosumab Effective for Bone Metastasis Following Prostate Cancer
June 28, 2010
- Daiichi Sankyo to Develop Vaccine Business in Japan and Emerging Markets
June 28, 2010
- Otsuka Gives Apple's iPad to Every MR
June 28, 2010
- Zometa Improves OS in Patients with De Novo Multiple Myeloma
June 28, 2010
- Bayer to Strengthen Marketing Structure in General Medicine
June 28, 2010
- Research-Driven Companies Also to Be Blamed for Jam of Generics: Mr Sawai
June 28, 2010
- Pfizer's Crizotinib to Contribute to Personalized Treatment of NSCLC
June 28, 2010
- MTPC Presents Business Improvement Plans to Korosho
June 28, 2010
- Ethical Drugs' Sales Up 10.2% in April: Crecon
June 28, 2010
- Sprycel Effective in First-Line Therapy for CML-CP
June 28, 2010
- Ensure Value-Matched Sales of Drugs: New JPMA Marketing Committee Chairman
June 28, 2010
- FPMAJ Subcommittee Calls For Full-Scale Introduction of Premium for Development of New Drugs
June 28, 2010
- 4-Year Follow-up Data from Sprycel-Treated Patients Announced
June 28, 2010
- Kowa Licenses Livalo to Abbott in Australia, New Zealand
June 28, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…